![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C13H16N2O |
Molar mass | 216.284 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Efaroxan is anα2-adrenergic receptorantagonist[1] andantagonist of theimidazoline receptor.
TheDarzens reaction between 2-fluorobenzaldehyde [57848-46-1] (1) and Ethyl 2-bromobutyrate [533-68-6] (2) gives ethyl 2-ethyl-3-(2-fluorophenyl)oxirane-2-carboxylate,CID:100942311 (3). A catalytic hydrogenation over Pd/C would give ethyl 2-[(2-fluorophenyl)methyl]-2-hydroxybutanoate,CID:77591056 (4).Saponification of the ester then gives 2-[(2-Fluorophenyl)methyl]-2-hydroxybutanoic acid,CID:53869347 (5). Treatment with 2 molar equivalents ofsodium hydride apparently gives 2-Ethyl-2,3-dihydrobenzofuran-2-carboxylic acid [111080-50-3] (6). Treatment of the carboxylic acid withthionyl chloride then gives the acid chloride and subsequent treatment of this withethylenediamine in the presence of trimethylaluminium completed the synthesis ofEfaroxan (8).
![]() | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |